Since angiotensin II is one of the most potent vasoconstrictors and an important stimulus for the secretion of aldosterone from the adrenal gland, the development of angiotensin II inhibitors is an important step in regulating blood pressure. This class of drug is well-tolerated by patients and these drugs have the added advantage over ACE inhibitors in that they are not associated with cough. Because most drugs can be given once daily and, like ACE inhibitors, they have a useful additive hypotensive effect in combination with diuretics, they are a welcome therapeutic tool in the treatment of hypertension.
This book addresses all aspects of white coat hypertension – the phenomenon of raised blood pressure in a medical setting yet not elsewhere – from its history to its pathophysiology, diagnosis and treatment. White coat hypertension is a common condition, accounting for 30–40% of the overall hypertensive population. While many studies have addressed this condition, controversy still exists over whether it causes an increased risk to sufferers and should be treated. In the volume neurogenic and non-neurogenic mechanisms are discussed and the significance of various predictive factors, evaluated. The association of white coat hypertension with dysmetabolic risk factors, new-onset diabetes and other conditions is carefully reviewed. Further chapters consider the occurrence of asymptomatic organ damage and cardiovascular outcomes in affected patients and helpful guidance is also provided on the controversial issue of when to treat and when not to treat. White Coat Hypertension is based largely on work done during the past 30 years by renowned researchers working in Milan, who have made key contributions in improving knowledge of the condition and whose work is well known across the world.
The sympathetic nervous system participates in the development and progression of the essential hypertensive state, as shown by increased circulating plasma levels of the adrenergic neurotransmitter norepinephrine, elevated norepinephrine spillover rate, and augmented sympathetic nerve traffic discharge detected in the high blood pressure state. In addition, the sympathetic overdrive participates in the development of the metabolic disarray as well as target organ damage frequently detected in this condition. The above mentioned sympathetic abnormalities explain why adrenergic overdrive represents an important therapeutic target in the treatment of hypertension.
Medievalists have long taught that highly emotional Christian devotion, often called ‘affective piety’, appeared in Europe after the twelfth century and was primarily practiced by communities of mendicants, lay people and women. Emotional monasticism challenges this view. The first study of affective piety in an eleventh-century monastic context, it traces the early history of affective devotion through the life and works of the earliest known writer of emotional prayers, John of Fécamp, abbot of the Norman monastery of Fécamp from 1028–78. Exposing the early medieval monastic roots of later medieval affective piety, the book casts a new light on the devotional life of monks in Europe before the twelfth century and redefines how medievalists should teach the history of Christianity.
This book addresses all aspects of white coat hypertension – the phenomenon of raised blood pressure in a medical setting yet not elsewhere – from its history to its pathophysiology, diagnosis and treatment. White coat hypertension is a common condition, accounting for 30–40% of the overall hypertensive population. While many studies have addressed this condition, controversy still exists over whether it causes an increased risk to sufferers and should be treated. In the volume neurogenic and non-neurogenic mechanisms are discussed and the significance of various predictive factors, evaluated. The association of white coat hypertension with dysmetabolic risk factors, new-onset diabetes and other conditions is carefully reviewed. Further chapters consider the occurrence of asymptomatic organ damage and cardiovascular outcomes in affected patients and helpful guidance is also provided on the controversial issue of when to treat and when not to treat. White Coat Hypertension is based largely on work done during the past 30 years by renowned researchers working in Milan, who have made key contributions in improving knowledge of the condition and whose work is well known across the world.
This volume presents a summary of recent research and debates on old and new aspects in stroke medicine. The volume covers topics such as causative factors of stroke such as hypertension, the immune system, genetic factors and the neurovegetative system, to the role of new imaging techniques in improving diagnosis and treatment, from preventive therapy and recanalization to the important and intriguing effects of neuroprotection, neuroregeneration and post stroke rehabilitation. Readers will be able to understand perspectives from stroke medicine researchers about the relationship between the nervous system and other physiological systems in the body and their role in the onset and treatment of stroke. The volume is intended as a resource for neurologists and medical professionals involved in other specialties such as cardiology, internal medicine, rehabilitation and physiology.
This will help us customize your experience to showcase the most relevant content to your age group
Please select from below
Login
Not registered?
Sign up
Already registered?
Success – Your message will goes here
We'd love to hear from you!
Thank you for visiting our website. Would you like to provide feedback on how we could improve your experience?
This site does not use any third party cookies with one exception — it uses cookies from Google to deliver its services and to analyze traffic.Learn More.